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ABSTRACT 
Objective: The present work entails design and characterization of enteric coated mucoadhesive microcapsules loaded with amoxicillin trihydrate 
as a novel chronotherapeutic approach for the treatment and management of bacterial infection. 
Methods: The microcapsules were prepared by solvent evaporation technique using ethyl cellulose (EC) and hydroxypropyl methylcellulose 
(HPMC) as rate-controlling and mucoadhesive polymers, followed by a triple coating with Eudragit L100 as enteric coating polymer. Box-Behnken 
statistical design (BBD) was applied for optimization of formulations containing EC, HPMCK100M and Eudragit L100 as factors for selected 
responses like entrapment efficiency, mucoadhesive property and drug release in 24 h. The optimized microcapsules were also characterized for 
particle size, drug content, swelling index, mucoadhesive strength, and in vivo antiulcer activity.  
Results: The optimized microcapsules exhibited good entrapment efficiency, particle size and mucoadhesive property. FT-IR studies revealed that 
there was no drug-polymer interaction. SEM studies revealed that microcapsules were non-aggregated, spherical in shape and smooth appearance. 
In vitro, drug release data from microcapsules was fitted to different kinetic models to explain release profiles. The correlation coefficient (r2) value 
indicated that drug release followed Higuchi model. Analysis of variance (ANOVA) showed a significant difference in the release of drug from all the 
prepared formulations at P<0.05 level. Accelerated stability study of optimized formulation (F4) up to 6 mo showed there was no change in drug 
content and release characteristics during storage. 
Conclusion: Overall, the present study indicated the successful development of mucoadhesive microcapsule. 
Keywords: Gastric resistance, Mucoadhesion, Swelling index, In vitro drug release, Antibacterial activity 




Amoxicillin trihydrate (AMT) is a semi-synthetic broad-spectrum β-
lactam antibiotic used for the treatment of bacterial infections. It is 
primarily active against gram positive bacteria by inhibiting their 
cell wall synthesis [1, 2]. It exhibits lower stability in gastric acid due 
to cleavage of C≡N bond of the β-lactam ring which leads to loss of 
potency with reduced oral bioavailability [3]. Further, low half-life 
(<1h) with relatively high oral dosage regimen (250-300 mg b. i. d/t. 
i. d) requires the development of a novel once-a-day oral chrono-
modulated drug delivery systems of AMT for the management of 
bacterial infections [4, 5]. 
Myriad formulation approaches have been tried viz. enteric coated 
tablets, sustained release mucoadhesive tablets, drug-coated beads and 
gastroretentive systems to protect the gastric degradation along with 
controlled drug absorption have limited fruition. Of late, polymeric 
microparticles appear to be the interesting device for their 
chronomodulated drug release mechanism satisfying the need of disease 
treatment [6]. Despite the more complex and onerous production of the 
multiple-unit systems, they have several advantages as compared to the 
single-unit products, including ready and uniform distribution in the 
gastrointestinal tract, minimizing the risk of local damage irritation 
caused by dose dumping. Furthermore, microparticles are less affected 
by pH change, gastric transit time, attain more constant plasma levels, 
give higher accuracy in reproducibility by dose and provide desired 
controlled release profile of drug delivery [7].  
As these mucoadhesive drug delivery systems contains a diverse class 
of polymers and other inactive ingredients which may invariably affect 
the desired performance of dosage form. In such case, rational use of 
Design of Experiment (DoE) helps a lot in optimizing drug delivery 
systems to obtain robust formulations. Several DoE methodologies are 
used for optimization such as factorial design (FD), Box-Behnken 
design (BBD), Central-composite design (CCD), D-optimal design 
(DOD), Plackett-Burman design (PBD) and mixture design [8]. Of late, 
BBD is most widely accepted for optimization and formulation 
development of microspheres as the design execution and 
interpretation is easier over other designs. It allows the utilization of 
three or more components followed by optimization to obtain robust 
formulations with desired performance characteristics [9-11]. 
Therefore, the current research work entails design and 
characterization enteric coated controlled release mucoadhesive 
microcapsules of amoxicillin trihydrate as a novel chronotherapeutic 
system using optimized polymer blend containing ethyl-cellulose 
along with mucoadhesive polymers like HPMCK4M, HPMCK15M, 
and HPMCK100M, sodium CMC, HEC and HPC. The mucoadhesive 
microcapsules were prepared by a solvent evaporation method and 
enteric coated by dip coating technique. The microcapsules showed 
complete protection of amoxicillin trihydrate in the gastric acidic 
environment to enhance the systemic availability of the drug with 
desired sustained release action and to improve the patient 
compliance due to its chronotherapeutic action. 
MATERIALS AND METHODS 
Amoxicillin trihydrate was generously gifted by M/s Ranbaxy Labs. 
Ltd., Gurgaon, India. The polymers ethyl cellulose, HPMCK4M, K15M, 
K100M were obtained from M/s Colorcon Ltd., Goa, India. The 
sodium CMC, HEC, HPC and EudragitL-100 were obtained from M/s 
Evonik Ltd., Mumbai, India. Solvents like acetone, light liquid 
paraffin, Tween 80 were purchased from M/s Loba Chem Pvt. Ltd., 
Mumbai, India, while all other chemicals and reagents like sodium 
hydroxide, potassium dihydrogen phosphate used were of analytical 
grade. De-ionized double distilled water was prepared by Millipore 
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filtration unit (M/s Millipore, Mumbai, India), used throughout the 
experimental work.  
Preparation of mucoadhesive microcapsules 
The microcapsules were prepared using ethyl cellulose by a solvent 
evaporation technique. After dissolving the ethyl cellulose (2000 
mg) and mucoadhesive polymer (1000 mg) in acetone (40 ml), 
amoxicillin trihydrate sodium (1000 mg) was added. The suspension 
was emulsified by light liquid paraffin (350 ml) containing Tween 80 
(10-12 drops). The emulsion was mechanically stirred at 500 rpm 
for 2.5 h to remove acetone.  
The microcapsules formed were collected by vacuum filtration, washed 
with n-hexane (250 ml) and air dried. The formulation composition of 
mucoadhesive microcapsules prepared is shown in table 1. 
 
Table 1: Composition of preliminary mucoadhesive microspheres of amoxicillin trihydrate 
Ingredients Formulation code 
F1 F2 F3 F4 F5 F6 F7 
Amoxicillin trihydrate 1 gm 1 gm 1 gm 1 gm 1 gm 1 gm 1 gm 
Ethyl cellulose 2 gm 2 gm 2 gm 2 gm 2 gm 2 gm 2 gm 
HPMC K4M _ 1 gm _ _ _ _ _ 
HPMC K15M _ _ 1 gm _ _ _ _ 
HPMC K100M _ _ _ 1 gm _ _ _ 
Sodium CMC _ _ _ _ 1 gm _ _ 
Hydroxyethyl cellulose _ _ _ _ _ 1 gm _ 
Hydroxypropyl cellulose _ _ _ _ _ _ 1 gm 
 
Preparation of enteric coated mucoadhesive microcapsules 
Enteric coating of mucoadhesive microcapsules was carried out by 
dip coating technique. The dried microcapsules were dipped into a 
coating solution containing Eudragit L100 (7.5%w/v) dissolved in 100 
ml of acetone with the help of forcep. The microspheres were air 
dried, and the process was repeated twice with different 
concentration of coating solution containing Eudragit L100 (10 % w/v 
and 12.5% w/v).  
Optimization using an experimental design 
For the systematic optimization of mucoadhesive microcapsule 
formulations, the experimental design methodology was employed by 
BBD with the help of Design-Expert software 8.0.5 (Stat-Ease Inc., MN). 
The BBD was specifically selected since it requires fewer treatment 
combinations than other experimental designs, which involves three 
to four factors to optimize the formulation performance using selected 
responses [12]. A 3-factor, 2-level (32) BBD was employed using 
concentration of EC(X1), HPMCK100M(X2)as selected factors, while 
percentage drug entrapment (Y1), percentage drug release 24h(Y2) 
and percentage mucoadhesion at 6h (Y3) were selected as obtained 
responses. The levels at which factors were investigated along with 
the obtained responses are shown in table 2. Total thirteen different 
formulations obtained were characterized for selected responses and 
analyzed for the effect of factors by response surfaces. Table 3 depicts 
the formulations prepared as per the experimental design along with 
observed responses. The optimized formulation was selected by 
numerical optimization. 
 
Table 2: Independent and dependent variables for experimental design optimization 
Independent variables (Factors) Range 
Low High 
X1 = Concentration of EC (gm) 
X2 = Concentration of HPMCK100 (gm) 







Dependent variables (Responses) Low High Goal 
Y1 = Drug entrapment (%) 
Y2 = Drug Release (%) 











Table 3: Experimental runs for the formulation of mucoadhesive microcapsules as per the experimental design 
Run X1 Conc. of 
EC (gm) 
X2 Conc. of 
HPMCK100 (gm) 
X3 Conc. of Eudragit L100 
(%w/v) 






1 1.00 0.75 12.50 65 58 74 
2 1.00 0.75 7.50 42 61 92 
3 1.50 0.50 12.50 66 44 75 
4 1.50 0.75 10.00 57 60 86 
5 2.00 1.00 10.00 59 69 84 
6 2.00 0.75 7.50 65 62 95 
7 2.00 0.50 10.00 55 41 85 
8 1.50 1.00 7.50 46 72 96 
9 1.50 0.75 10.00 55 65 87 
10 1.00 1.00 10.00 55 73 86 
11 2.00 0.75 12.50 64 65 76 
12 1.50 0.75 10.00 55 64 87 
13 1.50 0.50 7.50 44 42 97 
14 1.50 0.75 10.00 56 65 86 
15 1.00 0.50 10.00 57 40 84 
16 1.50 1.00 12.50 67 73 76 
17 1.50 0.75 10.00 58 63 87 
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Characterization of uncoated microcapsules 
Drug content 
Accurately weighed microcapsules, equivalent to 10 mg of 
amoxicillin trihydrate sodium were crushed in a mortar-pestle, 
dissolved in 100 ml of phosphate buffer pH 7.4, mixed well and 
sonicated. The resultant dispersion was kept for 24 h for complete 
mixing and filtered through a Whatman filter paper. The drug 
content was determined spectrophotometrically using UV-Visible 
spectrophotometer (Shimadzu, Japan) at 273 nm.  
Entrapment efficiency 
The entrapment efficiency of prepared microcapsules was 
determined by dissolving accurately weighed microcapsules, 
equivalent to 10 mg of amoxicillin trihydrate sodium in 100 ml of 
phosphate buffer pH 7.4. The resultant dispersion was kept for 24 h 
for complete mixing and filtered through a Whatman filter paper. 
The drug content was determined spectrophotometrically using UV-
Visible spectrophotometer (Shimadzu, Japan) at 273 nm. The 






Loose surface crystals study 
The drug encapsulated microcapsules were evaluated by loose surface 
crystal study to observe the excess drug present on the surface of 
microcapsules. Accurately weighed microcapsules, equivalent to 10 
mg of amoxicillin trihydrate sodium were weighed, mixed with 10 ml 
of phosphate buffer pH 7.4 for 5 min, shaken and then filtered through 
Whatman filter paper. The amount of drug present on the surface was 
determined spectrophotometrically using UV-Visible spectro-
photometer (Shimadzu, Japan) at 273 nm using regression equation 
(Y= 0.041X-0.006) derived from the standard plot, and calculated as a 
percentage of total drug content [13]. 
Swelling index 
The dynamic swelling property of microcapsules was determined in 
phosphate buffer pH 7.4. Accurately weighed microcapsules (20 mg) 
from different formulation were placed in dissolution media 
(phosphate buffer pH 7.4) for 24 h. The swollen microcapsules were 
collected by centrifugation at 2000 rpm and weighed. Further, the 
swollen microcapsules were dried by keeping on a filter paper and 
the weight was noted down [14]. The percentage swelling was then 






Where, Sw= Percentage of swelling of microcapsules, Wt = Weight of 
the microcapsules at time t in mg, Wo= Initial weight of the 
microcapsules in mg 
Percentage moisture loss 
The drug-loaded microcapsules were evaluated for percentage moisture 
loss which gives an idea about its hydrophilic nature. The microcapsules 
weighed 20 mg (W1) were initially kept in a desiccator containing 
calcium chloride at 37 °C for 24 h [15]. The final weight (W2) was noted 
when no further change in weight of the sample was observed. The 









Circulatory factors (Sphericity) 
The particle shape was measured by computing circulatory factor 
(S). The tracing obtained from the triangular microscope (Olympus 
ch20i, Mumbai, India) were used to calculate area (A) and perimeter 
(P) of the particles [13]. Finally, the circulatory factor (S) was 








Micromeritic properties of microcapsules 
Micromeritic properties of the microcapsules were determined by 
using the angle of repose, Carr’s index and Hausner’s ratio. The angle 
of repose was determined by the fixed funnel method. Carr’s Index 
and Hausner’s ratio were determined by tapping method. The 
microcapsules were tapped using USP tapped density tester 
(Electrolab-1020, Mumbai, India) for 1000 taps in a cylinder and the 
change in volume was measured[2,16]. The angle of repose, Carr‘s 















Where, h and r are the height and radius of the powder cone in cm, 
Bulk density and tapped density of the microcapsules are measured 
in gm/cm3. 
Fourier transform infrared (FTIR) spectroscopy 
FT-IR spectroscopic studies were employed to characterize the 
possible interactions, if any, between the drug and excipients. The 
FTIR spectra of samples of pure drug, a physical mixture of the drug 
with polymers and prepared microcapsules were recorded using 
KBr disc using an FTIR spectrophotometer (Shimadzu, Japan) [17]. 
Scanning electron microscopy (SEM)  
The shape and surface morphology of prepared microcapsules were 
observed by SEM (Joel Scanning Microscope JSM-5800, Japan). SEM 
analysis was carried out using an accelerating voltage of 20 kV after 
they were gold sputtered (Jeol 4B SVG-IN, Peabody, USA).  
In vitro wash off test 
Modified disintegrating apparatus was used for determination of a 
mucoadhesive property of the prepared microcapsules by in vitro 
adhesion testing method, also called as a wash-off test. A freshly 
excised piece of goat intestinal mucosa (5.5 × 1.5 cm) was mounted 
on a glass slide (5.5 × 1.5 cm) with cotton thread. Glass slide was 
connected with a suitable support. About 25 microcapsules were 
spread on this wet rinsed tissue specimen, and immediately 
thereafter the support was hung onto the arm of a USP tablet 
disintegrating apparatus. When the disintegrating apparatus was 
operated, the tissue specimen was subjected a slow, regular up and 
down movement in the test fluid (phosphate buffer, pH 7.4) at 37 °C. 
At specific time intervals like 0.5, 1, 2, 3, 4, 5 and 6 h, the apparatus 
was stopped and a number of microcapsules adhering to mucosal 
tissue were counted [18, 19]. Percentage mucoadhesion was 






In vitro drug release study 
The in vitro drug release from the mucoadhesive microcapsules 
were carried out using USP type II dissolution apparatus 
(Electrolab-TDT06L, Mumbai, India). The enteric coated 
microcapsules equivalent to 20 mg of amoxicillin trihydrate sodium 
were filled into the hard gelatin capsule, and subjected to dissolution 
in 900 ml of 0.1N HCl(pH 1.2) for initial 2 h followed by phosphate 
buffer (pH 7.4) up to 24 h, at 75rpm and 37 °±5 °C temperature. 
Sample aliquots of 5 ml were withdrawn periodically and replaced 
with 5 ml of the fresh media. The samples withdrawn were 
estimated for its drug content through UV spectroscopy at 273 nm 
and percentage drug release was calculated. The dissolution tests 
were performed in triplicate and the drug release data were fitted to 
various kinetic models like zero-order, first order, Higuchi, 
Korsmeyer-Peppas and Baker and Lansdale model [20, 21]. The 
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mean dissolution times (MDT) for 50% or 80% releases of the drug 

















Where j is the sample number, n is the number of dissolution sample 




and ΔMj is the additional amount of drug 
dissolved between tj and tj–1 
Antimicrobial assay 
The antimicrobial assay of the optimized bilayer tablets was 
performed by using an agar plate diffusion method. The zone of 
inhibition (ZOI) and MIC was calculated to evaluate the efficacy of the 
prepared bilayer tablet formulation vis-à-vis conventional marketed 
preparation. The different dilutions of pure drug amoxicillin trihydrate 
(standard) were prepared in pH 7.4 phosphate buffer with 
concentrations ranging from 1-250 µg/ml. The prepared bilayer 
tablets (test) and conventional marketed immediate release tablet 
preparation (Amoxil®, GlaxoSmithKline, India) of amoxicillin 
trihydrate were subjected to dissolution in pH 7.4 phosphate buffer 
using the same method as mentioned earlier. The aliquots collected 
from dissolution study at different time intervals were filtered through 
0.45 µm nylon filter and carefully transferred into the wells prepared 
on solidified agar plate in petridish inoculated with test organisms 
such as Staphylococcus aureus-ATCC29213 (gram positive cocci) and 
E. coli-ATCC25922 (gram negative bacilli) cultured at Department of 
Microbiology, Shri Venkateshwara University, Gajraula. The Petri dish 
was kept in an incubator at a controlled temperature (25 °C) 
condition. After 24h incubation, the ZOI for prepared bilayer tablets 
and marketed preparation were measured (in mm) and compared 
with a standard dilution of antibiotic in the concentrations of 0.5, 1, 2, 
3, 4, 6, 8 and 12 µg/ml. On the basis of ZOIs, the MIC was calculated 
with respect to the amount of drug release at each specified time 
interval responsible to reduce the viable growth of microorganisms. 
Statistical analysis 
Analysis of variance (ANOVA) was performed to find out significance 
difference among various formulations using Prism Graph Pad 
software (CA, USA). Two-way ANOVA was applied on the amount of 
drug release at 3 h, 6 hand 10 h from all formulations. 
Stability studies 
Accelerated stability studies were carried out for the optimized 
formulation as per ICH guidelines. Optimized microcapsules were 
packed in vials and stored at 40 °C/75% RH up to 6 mo in a stability 
chamber. In the specified time intervals the drugs content and in 
vitro drug release rate was determined [23]. 
RESULTS AND DISCUSSION  
Preparation of mucoadhesive microcapsules by experimental 
design 
Initially, various mucoadhesive polymers were tried for preparation 
of microcapsules of amoxicillin trihydrate by a solvent evaporation 
technique. The preliminary screening showed that microcapsules 
prepared with mucoadhesive polymer ethyl cellulose-based 
HPMCK100M provides higher stability and protection to the drug 
and they were found to be non-aggregated (table 1). The 
combination of polymers in a ratio of 1:2:1 w/w of drug: 
ethylcellulose: mucoadhesive polymer (HPMCK100M) showed the 
formation of microcapsules satisfactorily.  
Further, the microcapsules were prepared and optimized by 
employing BBD, at selected factors and levels. The response surface 
analysis was used to identify the effect of factors on the observed 
responses.  
The optimized formulation was selected based upon the levels of 
factors which yielded maximum entrapment efficiency, higher 
sustained release profile and maximum mucoadhesion strength. 
The response variables considered for systematic optimization, 
i.e., %drug entrapment, % drug release in 24 h and % 
mucoadhesion were allowed to fit in the quadratic equations 
with added interaction terms to correlate the studied responses 
with the examined factors. Statistical analysis and validation of 
the design was carried out by establishing mathematical 
relationships the form of polynomial equations for the measured 
responses as listed below:  
Y1 (% Drug entrapment) =-48.05147+45.00000×X1-11.50000×X2+ 
10.75000×X3+12.00000×X1×X2-4.80000×X1×X3-0.40000×X2×X3 
Y2 (% Drug release in 24 h) =+95.02500+29.10000×X1+2.70000×X2-
2.49000×X3-6.00000×X1×X2-0.20000×X1×X3+0.80000×X2×X3-
7.20000×X1-0.80000×X2-0.088000×X3 
Y3 (% Mucoadhesion in 6 h) =-49.27500+ 20.15000× X1+ 
215.80000×X2-1.51000×X3-10.00000×X1×X2+1.20000×X1×X3-
0.40000×X2×X3-7.80000×X1-91.20000×X2+8.00000-003×X3. 
The quadratic polynomial equation represents the quantitative 
effect of variables (X1, X2, and X3) and their interactions on the 
responses (Y1, Y2 and Y3). The values of the coefficients X1, X2 and 
X3 are related to the effect of these variables on the responses 
(Y1, Y2 and Y3). The positive sign represents synergistic effect, 
while a negative sign indicates an antagonistic effect. Fig. 1 
depicts the 3D response surfaces for the selected responses in 




Fig. 1: 3D-Response surfaces for different dependent variables: (A) Y1 (% drug entrapment), (B) Y2 (% drug release) and (C) Y3 (% 
mucoadhesion) as per the Box-Behnken experimental design 
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Fig. 1(A) represents the effects of X1 and X2 and their interaction on Y1 
(%drug entrapment) at a fixed level of X3. The response surface 
showed that entrapment efficiency was gradually increased with 
increase in the concentration of EC (X1), while with an increase in the 
concentration of HPMCK100M the entrapment efficiency was 
decreased. Fig. 1(B) represents the effect of X1 and X2 on response Y2 
(%drug release). The response surface showed that initially drug 
release was increased with increase in (X1) concentration of EC and at 
low level of HPMCK100M (X2), however, increase the concentration of 
HPMCK100M (X2) at a low level of EC (X1) revealed no significant 
increase in drug release. This indicated that HPMCK100M has no 
significant effect on drug release from microcapsules, while EC has a 
major role to sustain the release profile up to some extent. Fig. 1(C) 
indicated the effect of factor X1 and X2 on response Y3 (% 
mucoadhesion) and interaction between them. The response surface 
showed that % mucoadhesion was found to increase gradually with 
increase in the concentration of HPMCK100M (X2), however increasing 
the concentration of EC (X1) has no significant effect on mucoadhesion. 
From the response surface analysis, it has been concluded that HPMC 
has a major role on mucoadhesion and EC has a major role on drug 
release, however, the Eudragit L100 has no significant role on either of 
the responses Y1, Y2 and Y3. Hence, it was it taken as a null factor in all 
the experiments and during formulation development, the triple 
coating procedure was employed with a fixed concentration of enteric 
polymer. The model was evaluated by using two way ANOVA and the 
ANOVA results are enlisted in table 2. Finally, the optimized 
formulation for preparation of mucoadhesive microcapsules was 
selected by numerical optimization. 
 
Table 2: ANOVA results for various dependent variables Y1 (% drug entrapment), Y2 (% drug release) and Y3 (% mucoadhesion) as per 
the Box-Behnken experimental design 
ANOVA parameters Y1 (% drug entrapment) Y2  (% drug release) Y3 (% mucoadhesion) 
SS 756.50 801.29 1978.52 
df 6 9 9 
MS 126.08 89.03 219.84 
F-value 9.14 69.63 45.33 
Prob>F 0.0014 <0.0001 <0.0001 
Std. Deviation 3.71 1.13 2.20 
R2value 0.8458 0.9890 0.9831 
Suggested model Quadratic Quadratic Quadratic 
 
Enteric coated microcapsules by dip coating technique 
The enteric coated mucoadhesive microcapsules were prepared by 
dip coating mainly consists of three-layer coating of Eudragit L100. 
The coating composition for preparing enteric coated mucoadhesive 
microcapsules is shown in table 3. As a single layer and bilayer coat 
of enteric polymer on mucoadhesive microcapsules was unable to 
control the drug release in the gastric environment, therefore, 
trilayered coated microcapsules were prepared. The trilayered 
mucoadhesive microcapsules were found to protect the dosage form 
from the gastric acidic environment and allow the drug release in 
the intestinal fluid. 
  
Table 3: Enteric coating composition for the preparation of enteric coated mucoadhesive microcapsules 
S. No. Concentration of coating solution (%W/V) Enteric coating material Solvent Dissolution properties 
1 7.5 Eudragit L-100 Acetone (100 ml) >pH 6 
2 10 Eudragit L-100 Acetone (100 ml) >pH 6 
3 12.5 Eudragit L-100 Acetone (100 ml) >pH 6 
 
Drug content and entrapment efficiency 
The drug content and entrapment efficiency of uncoated 
microcapsules were determined and shown in table 4. Drug content 
and entrapment efficiency were found to be in the range of 
43.06±0.09 to 70.22±0.01 % and 44.87±0.19 to 70.48±0.12 % 
respectively. A formulation containing ethyl-cellulose with 
HPMCK100M based mucoadhesive microcapsules showed maximum 
drug content and entrapment efficiency in comparison to other 
formulations. The amoxicillin trihydrate being highly soluble in 
water is having a tendency to diffuse out to the aqueous medium 
even though the sufficiently higher drug entrapment. This is due to 
hindered diffusion of medicament through the gel barrier formed by 
mucoadhesive polymer [9, 13]. 
 
Table 4: Characterization parameters for uncoated mucoadhesive microcapsules 
Formulation 
code 
Drug content  
(%) (mean±SD) 
Entrapment efficiency  
(mean±SD) 
Loose surface crystal 
study (%) (mean±SD) 
Circulatory factors  
(mean±SD) 
Moisture loss (%) 
(mean±SD) 
F1 43.06±0.09 44.87±0.19 15.09±0.05 0.590±0.01 33.33±0.02 
F2 65.75±0.05 66.09±0.07 14.14±0.04 0.451±0.02 11.11±0.05 
F3 58.56±0.07 59.02±0.03 17.61±0.07 0.217±0.01 11.11±0.03 
F4 70.22±0.01 70.48±0.12 4.71±0.07 1.068±0.03 12.25±0.19 
F5 55.09±0.06 56.09±0.09 24.56±0.13 0.180±0.04 25.23±0.01 
F6 48.09±0.12 49.98±0.06 29.35±0.04 0.939±0.04 5.26±0.03 
F7 46.65±0.10 47.31±0.09 33.99±0.32 0.939±0.03 17.64±0.02 
F8 42.23±0.15 41.79±0.09 17.17±0.54 1.287±0.09 32.73±0.08 
F9 45.04±0.24 44.81±0.11 23.44±0.78 1.347±0.11 22.32±0.12 
Data expressed as mean±SD (n=3) 
 
Loose surface crystals study 
The loose surface crystal studies lend a hand to estimate the excess 
amount of free drug present on the surface of microcapsules in adsorbed 
form. The study was executed with various prepared formulations and 
the results were obtained (table 4).  
The loose surface crystal was found to be in the ranges of 4.71±0.07 to 
33.99±0.32%. The formulation prepared with EC and HPMCK100M 
showed minimum drug particles on the surface of microcapsules 
because HPMCK4M formed a thick viscous gel layer over the EC 
matrices and prevent the escape of drug crystals outside the gel 
barrier [13]. 
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Swelling index 
The swelling indexes of microcapsules prepared as per the experimental 
design were found to be satisfactory (table 5). Formulation F4 showed 
maximum swelling up to 230±0.08%, whereas formulation F7 showed 
minimum swelling of 30±0.07%, as shown in fig. 2. The maximum 
swelling depends on the type of polymer used, concentration, viscosity, 
ionic strength as well as the presence of water. The microcapsules were 
undergone into swelling event due to the presence of HPMCK100M.  
The swelling occurs when the polymer absorbs water and depends on 
the viscosity grade and ionic strength of the polymer [13, 27]. 
 
Table 5: Swelling index of uncoated mucoadhesive microcapsules 
Formulation code Swelling index (mean±SD) 
1h 2 h 3 h 4 h 5 h 24 h 
F1 50±0.04 25±0.13 30±0.04 45±0.05 20±0.10 50±0.13 
F2 20±0.10 20±0.13 40±0.05 64±0.07 100±0.04 100±0.13 
F3 10±0.13 45±0.05 60±0.08 60±0.10 80±0.08 170±0.03 
F4 90±0.08 125±0.03 110±0.05 85±0.04 225±0.03 230±0.08 
F5 30±0.08 70±0.10 45±0.04 25±0.08 55±0.07 60±0.07 
F6 20±0.03 105±0.07 20±0.03 60±0.10 105±0.03 45±0.05 
F7 15±0.07 65±0.05 25±0.13 55±0.10 30±0.04 30±0.07 
F8 35±0.19 53±0.18 34±0.07 43±0.04 55±0.04 65±0.16 
F9 47±0.19 33±0.04 25±0.11 36±0.04 67±0.04 41±0.21 
Data expressed as mean±SD (n=3) 
 
 
Fig. 2: Swelling index of the mucoadhesive microcapsules after 24h; Data expressed as mean±SD (n=3) 
 
Percentage moisture loss 
The percentage moisture loss by various mucoadhesive micro-
capsule formulations prepared as per experimental design are 
shown in table 4. The minimum moisture loss was observed with 
formulation F4 and maximum moisture loss was observed with 
formulation F1, which ensures the presence of water content in 
the prepared microcapsule due to hygroscopic nature of the drug 
or mucoadhesive polymer. However, low proportion of water 
indicated proper drying and instant hardening of microcapsule 
upon storage [28]. 
Circulatory factors (Sphericity) 
The circularity factor for mucoadhesive microcapsules was found to 
be very close to 1.00, confirm their spherical nature as observed 
from the table 4. Further, the SEM was used for better 
understanding of the morphology of the microcapsules. 
Micromeritic properties 
Table 6 enlists data on the micromeritic properties of the prepared 
microcapsules. The average particle size of microcapsules was found 
to be between 46.89±0.04 and 80.66±0.03 µm. The particle size 
depends on the amount, type or concentration of polymers used in 
the formulation which increases the viscosity of the solution. The 
tapped density was found to be between 0.312±0.02 to 0.5±0.07 
gm/cm3 and bulk density was found to be between 0.234±0.01 to 
0.468±0.03 gm/cm3. The Carr’s Index was found in the range from 
3.12±0.13 to 16.36±0.03%. The Carr’s Index was found less than 17 
%, showed good flow property. Hausner’s ratio of mucoadhesive 
microcapsules was found to be less than 1.33±0.03 indicated good 
flow property of the prepared microcapsules. The angle of repose 
was found to be between 11.04±0.04 to 43.27±0.02 degree. From 
the values of angle of repose maximum data are less than 30° which 
indicate good flow property as compared to the drug [29]. 
 
Table 6: Micromeritic properties of prepared uncoated mucoadhesive microcapsules 
Formulation 
code 
















F1 50.22±0.01 0.312±0.02 0.234±0.01 43.27±0.02 1.33±0.01 15.00±0.01 
F2 63.33±0.13 0.483±0.08 0.468±0.01 18.85±0.08 1.03±0.03 3.12±0.13 
F3 50.12±0.13 0.483±0.06 0.405±0.08 17.52±0.07 1.19±0.08 16.21±0.13 
F4 49.33±0.04 0.531±0.07 0.468±0.03 11.04±0.04 1.06±0.01 6.25±0.04 
F5 46.89±0.05 0.539±0.04 0.375±0.03 24.94±0.08 1.33±0.03 16.36±0.03 
F6 80.66±0.03 0.433±0.08 0.382±0.09 28.21±0.03 1.13±0.09 11.76±0.03 
F7 52.66±0.08 0.365±0.03 0.388±0.05 29.43±0.13 1.21±0.05 12.99±0.08 
F8 66.01±0.10 0.455±0.04 0.503±0.08 33.08±0.17 1.67±0.06 18.44±0.10 
F9 43.67±0.12 0.539±0.07 0.375±0.10 21.35±0.09 1.25±0.08 10.33±0.15 
Data expressed as mean±SD (n=3) 
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Fourier transform infrared (FTIR) spectroscopy  
The FT-IR spectra of pure drug, a physical mixture of the drug 
with polymers and drug-loaded microcapsule are shown in fig. 3. 
The peak at 3583 cm-1 indicated-NH stretching, 1157 cm-1 
indicated C-O-C symmetric stretching, 10298 cm-1 for–S=O 
stretching, 1384 cm-1 indicated–C-N vibrations and 1693 cm-1for 
aromatic–C=N stretching. It was observed from the spectra’s of 
pure drug and optimized formulations that there was neither 
remarkable shift in the wave number of the peaks nor in the 
intensity of peaks proved that there was no interaction between 
drug and selected polymers [17]. 
 
 
Fig. 3: FT-IR spectra of pure drug (amoxicillin trihydrate) (A); Physical mixture of pure drug+EC (B); Physical mixture of pure 
drug+EC+HPMCK100M (C); Optimized mucoadhesive microcapsule formulation (D) 
 
 
Fig. 4: SEM images of microcapsules of optimized mucoadhesive microcapsule formulation (A), broken microcapsules (B), optical 
microscopy images of microcapsules of optimized formulation (C) and optimized enteric coated microcapsules (D) 
 
Scanning electron microscope (SEM)  
The microcapsules were found to be discrete, non-aggregated, free-
flowing and monolithic matrix type. Fig. 4 depicts the SEM 
photographs, which indicated that the microcapsules were spherical 
and completely covered with the coating polymer. 
In vitro wash-off test  
Fig. 5 represents the percentage mucoadhesion exhibited by different 
batches of prepared mucoadhesive microcapsules. In vitro wash-off 
test showed that prepared microcapsules exhibited fair mucoadhesive 
property. The wash-off was faster at intestinal pH medium due to 
critical degree of hydration, molecular weight and mobility, ionic 
content, solubility and viscosity of the mucoadhesive polymers. The 
rapid wash-off observed at intestinal pH 7.4 is due to ionization of 
carboxyl and other functional groups in the polymers at this pH, which 
increases their solubility and reduces bioadhesive strength (table 7). 
The formulations containing a higher concentration of mucoadhesive 
polymer (HPMCK100M) showed higher mucoadhesion property and 
longer wash-off time attributed due to the electrostatic attraction 
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between HPMC and mucin. Also, the swelling index of the polymer 
affects the mucoadhesion property significantly. Higher swelling leads 
to the attachment of the microcapsules with mucosal surface for a 
longer period of time and showed slower wash-off [17, 18]. 
 
 
Fig. 5: % Mucoadhesion of microcapsules of different formulations after 6 h; data expressed as mean±SD (n=3) 
 
Table 7: % Mucoadhesion of mucoadhesive microcapsules during in vitro wash off test 
Formulation code % Mucoadhesion (mean±SD) 
0.5 h 1h 2h 3h 4h 5h 6h 
F1 12±1 12±1 12±1 8±2 0 0 0 
F2 80±3 64±3 44±3 28±1 20±3 20±3 16±2 
F3 72±3 44±3 32±3 28±2 24±2 16±2 16±3 
F4 100±1 100±1 100±1 72±1 72±3 72±3 72±2 
F5 76±2 48±1 44±1 40±2 32±3 12±2 8±2 
F6 60±3 48±2 16±2 12±1 12±1 12±1 12±1 
F7 20±2 20±3 20±3 16±2 36±3 16±1 10±2  
F8 18±1 23±2 33±1 12±3 33±1 25±2 13±1  
F9 45±2 17±3 23±3 10±1 24±2 22±3 23±3  
Data expressed as mean±SD (n=3) 
 
Gastric-resistance of enteric coated microcapsules 
The dissolution was carried out in the acidic medium (0.1N HCl) for 
first 2 h and it was found that there was no release of drug from the 
enteric coated microcapsules. The microcapsules remain intact 
during the acidic medium because the degree of ionization of 
carboxylic acid groups in the Eudragit L-100 increases with pH of 
the medium and remains intact in the acidic medium, and prevents 
drug release. In alkaline medium initially the enteric coating retard 
the drug release to some extent but as the enteric coating has no 
effect on drug release due to rapid dissolution of the coating layer in 
phosphate buffer pH 7.4, hence the drug release depends on the 
viscosity of the mucoadhesive polymer present in the mucoadhesive 
microcapsules. Thus, enteric coated microcapsules provide good 
barrier property against under low pH conditions to prevent drug 
diffusion [26]. 
In vitro drug release study 
The in vitro drug release showed that enteric-coated microcapsules 
provide a good barrier against drug diffusion under acidic pH 
conditions to protect the drug from degradation. The drug release 
was found to be sustained up to 24 h and depends on the 
concentration of HPMCK100, viscosity/molecular weight. The 
cumulative % drug release from mucoadhesive microcapsules was 
significantly decreased with an increase in the drug-polymer ratio 
(HPMCK100M) as compared to the EC. In the present study, 
HPMCK100M was used as a hydrophilic matrix agent because it 
forms a strong viscous gel on contact with aqueous media, which 
may be useful in the controlled delivery of highly water-soluble 
drugs. Faster release of the drug from the hydrophilic matrix was 
probably due to faster dissolution of the highly water-soluble drug 
from the core and its diffusion out of the matrix forming the pores 
for entry of solvent molecules. Incorporation of ethyl cellulose has 
little effect on controlling the release rate rather it helps in 
microencapsulation of the active pharmaceuticals [31].  
Fig. 6 depicts the cumulative in vitro drug release from the 
enteric coated mucoadhesive microcapsule formulations 
prepared as per experimental design. From the in vitro drug 
release study the formulation F4 was considered as an optimized 
formulation with optimum mucoadhesion, swelling and 
sustaining drug release pattern. The mean dissolution data was 
calculated showed that formulation F4 with maximum MDT 
(10.17 h) and formulation F7 showed minimum MDT (3.68 h), 
indicated that the drug release was faster at low concentration 
of HPMCK100M and intermediate concentration of EC. MDT50%, 
the value of optimized formulation was found to be 7.05 h. 
Increase in MDT value indicated that the drug release is slower, 
which is attributed due to increase in the thickness of barrier 
layers HPMC on the matrix core. 
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Fig. 6: Cumulative % drug release profiles of different formulations; Data expressed as mean±SD (n=3) 
 
Mathematical modeling of kinetic data obtained revealed that 
drug release from trilayer microcapsules showed non-Fickian 
diffusion or super case type-II (n>1.0) mechanism. The higher 
(r2) value signifies that the developed layered microcapsules 
follow Higuchi kinetics and represents a swellable system [13, 
20, 31] (table 8). 
 
Table 8: Various parameters of the model equations on the in vitro drug release kinetics 
Formulation code Zero-order First order Higuchi model Korsmeyer-peppa’s model Baker-lansdale model 
r2 K0 r2 K1 r2 Kh r2 n r2 K 
F1 0.966 -11.01 0.863 0.172 0.949 -56.90 0.869 1.541 0.966 0.011 
F2 0.924 -14.48 0.629 0.274 0.935 -63.37 0.846 1.767 0.935 0.145 
F3 0.947 -11.85 0.776 0.198 0.949 -58.81 0.855 1.606 0.944 0.128 
F4 0.955 -9.58 0.788 0.138 0.957 -52.37 0.873 1.481 0.955 0.096 
F5 0.836 -18.10 0.737 0.453 0.878 -75.99 0.818 1.945 0.836 0.179 
F6 0.884 -21.12 0.944 0.324 0.878 -79.59 0.829 2.085 0.884 0.214 
F7 0.812 -26.18 0.946 0.451 0.813 -89.05 0.810 2.310 0.812 0.264 
F8 0.849 -20.04 0.962 0.433 0.820 -77.51 0.833 1.876 0.982 0.187 
F9 0.883 -22.28 0.987 0.467 0.834 -82.04 0.846 1.662 0.957 0.192 
r2=Coefficient of correlation, K0, K1, Kh, K= Release rate constants for zero order, first order, Higuchi, Korsmeyer-Peppas and Baker-Lansdale model 
 
Antimicrobial assay 
Table 9 and 10 depicts the ZOI of standard dilutions of pure 
antibiotic, prepared bilayer tablets and marketed tablet formulation. 
It has been observed that as per the designed drug release profiles, 
there was a significant decrease in ZOI of the bilayer tablet 
formulation at 3 hr of dissolution with value 19.3 mm and 22.0 mm 
for G. positive cocci and G. negative bacilli, which matched with the 
ZOI of pure drug with dilution at 2 µg/ml. On the contrary, the 
marketed formulation showed ZOI value of 29.3 mm and 29.7 mm, 
which were matched with the ZOI of the pure drug with dilution at 5 
µg/ml. This indicated that bilayer tablet formulation has lower value 
of MIC vis-à-vis the marketed formulation in both gram positive as 
well as gram negative microorganisms. Moreover, the prepared 
formulation indicated higher efficacy of chronomodulated release 
bilayer tablet formulation over the conventional marketed product. 
 
Table 9: Antibiotic sensitivity of pure drug at standard dilution against 
Conc. (µg/ml) ZOI (in mm±SD) for gram positive cocci ZOI (in mm±SD) for gram negative bacilli 
0 0±0.00  0±0.00  
1 0±0.00  0±0.00  
2 19.1±2.5  18.0±2.6  
5 23.2±1.6 22.9±2.2 
10 28.2±2.0 30.1±1.4 
15 33.2±1.7  34.8±2.0  
20 40.5±1.4 38.4±1.3 
50 46.4±2.6  43.6±2.6  
100 51.2±1.4 45.8±1.6 
200 53.4±1.7 50.2±1.7 
250 56.3±1.9 55.3±2.2  
Data expressed as mean±SD (n=3) 
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Table 10: Antibiotic sensitivity of optimized mucoadhesive microcapsules and marketed formulation of amoxicillin trihydrate 
Dissolution 
time (h) 
Optimized microcapsules Marketed product (Amoxil) 
ZOI (in mm±SD) for gram 
positive cocci 
ZOI (in mm±SD) for gram 
negative bacilli 
ZOI (in mm±SD) for gram 
positive cocci 
ZOI (in mm±SD) for gram 
negative bacilli 
0 0±0.00 0±0.00 0±0.00 0±0.00 
0.5 7.6±2.07 10.2±3.10 12.8±2.07 16.2±2.10 
1 10.4±1.53 13.3±2.33 19.0±3.51 21.3±1.09 
2 12.9±3.06 16.3±3.53 21.7±3.06 25.2±1.80 
3 18.3±3.91 21.0±1.00 20.3±3.93 28.7±2.90 
4 31.2±2.02 30.7±1.38 30.4.±2.00 36.9±1.05 
5 35.7±2.59 36.7±3.08 33.7±2.92 38.3±2.10 
6 42.4±1.03 39.7±4.53 41.7±1.53 40.1±2.01 
8 47.1±4.01 40.7±3.06 44.7±2.01 42.7±2.32 
12 49.1±2.04 42.0±1.03 46.7±1.05 44.4±1.07 
Data expressed as mean±SD (n=3) 
 
Stability studies 
The accelerated stability studies of the optimized formulation 
showed that prepared microcapsules were stable for 6 mo without 
any change in physiochemical parameters. The drug content and 
dissolution rate of the formulations showed no significant change 
upon storage [23]. 
CONCLUSION 
The mucoadhesive microcapsules of amoxicillin trihydrate were 
prepared effectively using a polymeric blend of ethyl cellulose and 
HPMCK100M. The gastric protection of drug release from 
mucoadhesive microcapsules was achieved by trilayer enteric 
coating with Eudragit L100 using novel dip coating technique. The 
physiochemical characterization of microcapsules was found to be 
satisfactory. The microcapsules exhibited good mucoadhesive 
properties under in vitro test conditions. In vitro drug release 
studies showed that mucoadhesive microcapsules well control drug 
release over an extended period of time. In vitro microbiological 
studies showed the superior antimicrobial effect of enteric coated 
mucoadhesive microcapsules on E. coli and S. aureus strains vis-à-vis 
conventional marketed formulation. Stability studies revealed that 
optimized microcapsules remained stable for 6 mo period of time 
with no change in drug content and dissolution profile. 
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